Oak Ridge Investments’s Emergent Biosolutions EBS Stock Holding History

Oak Ridge Investments’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-57,417	Closed	-$2.88M	–	171
2021 Q3	$2.88M	Sell	57,417 -2,450	-4%	-$148K	0.25%	105
2021 Q2	$3.77M	Sell	59,867 -5,521	-8%	-$355K	0.33%	101
2021 Q1	$6.08M	Buy	65,388 +1,505	+2%	+$154K	0.57%	70
2020 Q4	$5.72M	Buy	+63,883	New	+$5.86M	0.5%	77

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Oak Ridge Investments's EBS Position: Q4 2021 in Review

Oak Ridge Investments sold out of Emergent Biosolutions (EBS) in Q4 2021, closing a stake of 57,417 shares — an estimated $2.88M sold.

Oak Ridge Investments first reported a position in EBS in Q4 2020 and held it in 4 quarters. The position peaked at $6.08M in Q1 2021. 254 funds tracked by Wall St. Rank hold EBS as of Q4 2021.

Oak Ridge Investments reported no remaining Emergent Biosolutions position as of Q4 2021 after selling out during the quarter.
Oak Ridge Investments sold 57,417 Emergent Biosolutions shares in Q4 2021, an estimated $2.88M.
Oak Ridge Investments first reported a position in Emergent Biosolutions in Q4 2020 and held it in 4 quarters.
Oak Ridge Investments's Emergent Biosolutions position peaked at $6.08M in Q1 2021.
254 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2021.

Based on Oak Ridge Investments's 13F filing for Q4 2021, filed 1 Feb 2022.